U.S. MARKETS FOR DIAGNOSTIC ONCOLOGY-RELATED MAGNETIC RESONANCE AND NUCLEAR/MOLECULAR MEDICINE IMAGING SYSTEMS

180 Pages | 37 Exhibits | 2014 Analysis | Forecasts Through 2018

OVERVIEW:
It is estimated that nearly 1.7 million people in the United States (U.S.) will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. Despite advancements in oncology (the branch of medicine that deals with cancer), the disease remains the second-leading cause of death in the country after heart disease. Today, a constellation of methods are used in the fight against cancer, including diagnostic imaging modalities such as magnetic resonance imaging (MRI) and nuclear/molecular medicine imaging (NMMI), which allow physicians to detect malignancies at their most treatable stages.

In the U.S., approximately 15.1 million diagnostic oncology-related MRI and NMMI procedures were performed in 2013. Together, these procedures generated approximately $595.9 million in corresponding systems sales; it is expected that during the forecast period covered by this report, sales of these systems for diagnostic oncology-related indications will increase at a compound annual rate of 5.5%, reaching an estimated $780.1 million in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related MRI and NMMI systems arena.

Covered topics in this report include a statistical overview of cancer in the U.S. including cancer incidence and prevalence, cancer-related deaths, and cancer risk factors; MRI applications and indications; MRI computer-aided detection; MRI systems including bore-less, enclosed, flared-gantry, intraoperative, open, and wide-bore models; NMMI applications and indications; positron emission tomography (PET) and hybrid PET systems; radioisotope/radiopharmaceutical shortages; single-photon emission computed tomography (SPECT) and hybrid SPECT systems, total and diagnostic oncology-related MRI and NMI procedures volumes and market forecasts, among others.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Cancer Overview
ii. Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Systems Market
	a. Magnetic Resonance Imaging Market Segment
	b. Nuclear/Molecular Medicine Imaging Systems Market Segment
iii. Methodology

Exhibit ES-1: Estimated New Cases, Prevalence,and Deaths for Selected Types of Cancer
Exhibit ES-2: Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
Exhibit ES-3: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
Exhibit ES-4: Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
Exhibit ES-5: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
Exhibit ES-6: Magnetic Resonance Imaging Systems, Market Forecast, 2013-2018
Exhibit ES-7: Nuclear/Molecular Medicine Imaging Systems, Market Forecast, 2013-2018

1. CANCER STATISTICS UPDATE

1.1 Acquired Capabilities of Cancer Cells
1.2 Cataloging Genomic Alterations Involved in the Development of Cancer
1.3 Risk Factors Associated with the Development of Cancer
1.4 Cancer Staging
1.5 New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
1.6 Clinical and Statistical Data for Selected Types of Cancer
	1.6.1 Brain and Other Nervous System Cancers
		1.6.1.1 Etiology
		1.6.1.2 Epidemiology
	1.6.2 Breast Cancer
		1.6.2.1 Etiology
		1.6.2.2 Epidemiology
	1.6.3 Colorectal Cancer
		1.6.3.1 Etiology
		1.6.3.2 Epidemiology
	1.6.4 Kidney/Renal Pelvis Cancer
		1.6.4.1 Etiology
		1.6.4.2 Epidemiology
	1.6.5 Leukemia
		1.6.5.1 Etiology
		1.6.5.2 Epidemiology
	1.6.6 Lung/Bronchus Cancer
		1.6.6.1 Etiology
		1.6.6.2 Epidemiology
	1.6.7 Lymphoma
		1.6.7.1 Etiology
		1.6.7.2 Epidemiology
	1.6.8 Melanoma
		1.6.8.1 Etiology
		1.6.8.2 Epidemiology
	1.6.9 Oral Cavity and Pharyngeal Cancers
		1.6.9.1 Etiology
		1.6.9.2 Epidemiology
	1.6.10 Ovarian Cancer
		1.6.10.1 Etiology
		1.6.10.2 Epidemiology
	1.6.11 Pancreatic Cancer
		1.6.11.1 Etiology
		1.6.11.2 Epidemiology
	1.6.12 Prostate Cancer
		1.6.12.1 Etiology
		1.6.12.2 Epidemiology
	1.6.13 Thyroid Cancer
		1.6.13.1 Etiology
		1.6.13.2 Epidemiology
	1.6.14 Urinary Bladder Cancer
		1.6.14.1 Etiology
		1.6.14.2 Epidemiology
	1.6.15 Uterine Cancer
		1.6.15.1 Etiology
		1.6.15.2 Epidemiology

Exhibit 1-1: Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer
Exhibit 1-2: Brain and Other Nervous System Cancers, Facts And Figures
Exhibit 1-3: Breast Cancer, Facts And Figures
Exhibit 1-4: Colorectal Cancer, Facts And Figures
Exhibit 1-5: Kidney/Renal Pelvis Cancers, Facts And Figures
Exhibit 1-6: Leukemia, Facts and Figures
Exhibit 1-7: Lung/Bronchus Cancer, Facts And Figures
Exhibit 1-8: Hodgkin Lymphoma, Facts and Figures
Exhibit 1-9: Non-Hodgkin Lymphoma, Facts and Figures
Exhibit 1-10: Melanoma of the Skin, Facts and Figures
Exhibit 1-11: Oral Cavity and Pharyngeal Cancers, Facts and Figures
Exhibit 1-12: Ovarian Cancer, Facts and Figures
Exhibit 1-13: Pancreatic Cancer, Fact and Figures
Exhibit 1-14: Prostate Cancer, Facts And Figures
Exhibit 1-15: Thyroid Cancer, Fact and Figures
Exhibit 1-16: Urinary Bladder Cancer, Fact and Figures
Exhibit 1-17: Cancer of the Uterine Corpus, Facts and Figures
Exhibit 1-18: Cancer of the Uterine Cervix, Facts and Figures

2. U.S. MARKETS FOR DIAGNOSTIC ONCOLOGY-RELATED MAGNETIC RESONANCE AND NUCLEAR/MOLECULAR MEDICINE IMAGING SYSTEMS

2.1 Magnetic Resonance Imaging Systems, Market Analysis
	2.1.1 Technologies
	2.1.2 Procedure Volumes
	2.1.3 Products
	2.1.4 Market Forecast
	2.1.5 Competitive Analysis
2.2 Nuclear/Molecular Medicine Imaging Systems, Market Analysis
	2.2.1 Technologies
		2.2.1.1 Imaging with Positron Emission Tomography Scanners
		2.2.1.2 Imaging with Gamma Cameras
		2.2.1.3 Imaging with Hybrid Devices
	2.2.2 Procedure Volumes
	2.2.3 Products
	2.2.4 Market Forecast
	2.2.5 Competitive Analysis

Exhibit 2-1: Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
Exhibit 2-2: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
Exhibit 2-3: Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
Exhibit 2-4: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
Exhibit 2-5: Magnetic Resonance Imaging, Procedure Volumes Forecast, 2013-2018
Exhibit 2-6: 2014, Selected Magnetic Resonance Imaging Systems
Exhibit 2-7: Magnetic Resonance Imaging Systems, Market Forecast, 2013-2018
Exhibit 2-8: 2013, Magnetic Resonance Imaging Systems Market, Share by Supplier
Exhibit 2-9: Nuclear/Molecular Medicine Imaging, Procedure Volumes Forecast, 2013-2018
Exhibit 2-10: 2014, Selected Nuclear/Molecular Medicine Imaging Systems
Exhibit 2-11: Nuclear/Molecular Medicine Imaging Systems, Market Forecast, 2013-2018
Exhibit 2-12: 2013, Nuclear/Molecular Medicine Systems Market, Share by Supplier

3. COMPANY PROFILES

3.1 Digirad Corporation
3.2 Esaote North America, Inc./Esaote SPA
3.3 GE Healthcare, Inc./General Electric Company
3.4 Hitachi Medical Systems America, Inc./Hitachi Medical Corporation/Hitachi LTD
3.5 IntraMedical Imaging LLC
3.6 NeuroLogica Corporation/Samsung Electronics America, Inc./Samsung Electronics Co LTD/Samsung Group
3.7 Neusoft Medical Systems Co LTD/Neusoft Corporation
3.8 Philips Healthcare, Inc./Royal Philips NV
3.9 Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
3.10 Toshiba America Medical Systems, Inc./Toshiba Corporation

APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Analogic Corporation
  2. Brainlab AG
  3. CMR Naviscan Corporation/Compania Mexicana de Radiologia CRG, SA de CV
  4. Copley Controls/Analogic Corporation
  5. Digirad Corporation
  6. Dilon Technologies, Inc.
  7. Esaote North America, Inc./Esaote SPA
  8. FONAR Corporation
  9. Gamma Medica/Psilos Group
  10. GE Healthcare, Inc./General Electric Company
  11. Hitachi Medical Systems America, Inc./Hitachi Medical Corporation/Hitachi LTD
  12. Hologic, Inc.
  13. iCAD, Inc.
  14. IMRIS, Inc.
  15. IntraMedical Imaging LLC
  16. Invivo/ Royal Phiips NV
  17. Mediso Medical Imaging Systems/Mediso LTD
  18. Medtronic, Inc.
  19. Merge Healthcare, Inc.
  20. MRI Interventions, Inc.
  21. NeuroLogica Corporation/Samsung Electronics America, Inc./Samsung Electronics Co., LTD/Samsung Group
  22. Neusoft Medical Systems Co., LTD/Neusoft Corporation
  23. Philips Healthcare, Inc./ Royal Philips NV
  24. Samsung Electronics Co., LTD/ Samsung Group
  25. Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  26. Toshiba America Medical Systems, Inc./Toshiba Corporation
  27. UltraSPECT, Inc./UltraSPECT LTD
  28. XBO Medical Systems Co., LTD
Contact Us

Need help finding medtech research? Let us help you!